8.54
+0.4(+4.91%)
Currency In USD
| Previous Close | 8.14 |
| Open | 8.08 |
| Day High | 8.62 |
| Day Low | 8.08 |
| 52-Week High | 32.2 |
| 52-Week Low | 3.44 |
| Volume | 59,220 |
| Average Volume | 164,030 |
| Market Cap | 63.03M |
| PE | -1.63 |
| EPS | -5.23 |
| Moving Average 50 Days | 7.4 |
| Moving Average 200 Days | 8.93 |
| Change | 0.4 |
If you invested $1000 in Biodesix, Inc. (BDSX) since IPO date, it would be worth $33.33 as of December 04, 2025 at a share price of $8.54. Whereas If you bought $1000 worth of Biodesix, Inc. (BDSX) shares 3 years ago, it would be worth $298.6 as of December 04, 2025 at a share price of $8.54.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Biodesix to Present New Data at Two Major Upcoming Scientific Meetings
GlobeNewswire Inc.
Yesterday at 1:22 PM GMT
Clinical utility data for Nodify Lung® tests to be presented at North American Conference on Lung Cancer (NACLC) highlighting potential for earlier diagnosis of lung cancer Development data for a new ultra-sensitive ESR1 assay for breast cancer treat
Biodesix to Share its R&D Roadmap during its Corporate Day Presentation at AMP Annual Meeting
GlobeNewswire Inc.
Oct 30, 2025 10:17 AM GMT
Speaker panel will include collaborative case study presentations from strategic partners: Memorial Sloan Kettering Cancer Center, Bio-Rad Laboratories, and Thermo Fisher ScientificLOUISVILLE, Colo., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc.
Biodesix Announces Expanded Bio-Rad Laboratories Partnership Agreement to Develop Droplet Digital™ PCR High Complexity Assays
GlobeNewswire Inc.
Oct 22, 2025 10:17 AM GMT
Biodesix will perform the clinical validation of ddPLEX ESR1 Mutation Detection Assay for advanced breast cancer testingLOUISVILLE, Colo., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NYSE: BDSX), a leading diagnostics solutions company, today